How many drugs treat Nicotine dependence?

Drug Landscape tracks 4 marketed treatments for Nicotine dependence (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/nicotine-dependence.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nicotine dependence — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nicotine dependence (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Nicotine dependence, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Nicorette	NICOTINE	Sanofi	Cholinergic Nicotinic Agonist [EPC]	Neuronal acetylcholine receptor; alpha4/beta2	1991-01-01
Wellbutrin	bupropion	GSK (GlaxoSmithKline)	NDRI (Norepinephrine-dopamine reuptake inhibitor)	Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor	1985-12-30
Wellbutrin	Wellbutrin	Mclean Hospital		Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor
Elontril	Elontril	Boehringer Ingelheim		Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Boehringer Ingelheim · 1 drug in Nicotine dependence
GSK (GlaxoSmithKline) · 1 drug in Nicotine dependence
Mclean Hospital · 1 drug in Nicotine dependence
Sanofi · 1 drug in Nicotine dependence

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Nicotine dependence:

Cite this brief

Drug Landscape (2026). Nicotine dependence — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nicotine-dependence. Accessed 2026-06-10.

Nicotine dependence full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing